Sign In

Lee Buckler

President & CEO, Director at RepliCel Life Sciences Inc.

Lee Buckler, the President & CEO of RepliCel Life Sciences, a leading figure in developing cell therapies for various conditions including pattern baldness, aging & sun-damaged skin, and chronic tendinopathy.

With a rich background in both for-profit and non-profit organizations in the cell therapy regenerative medicine industry, Lee Buckler has been an executive in the field since the early 2000s.

Before venturing into biotech, Lee Buckler pursued a Bachelor of Laws degree from The University of British Columbia and a BEd in Social Sciences from Canadian University College.

Throughout his career, Lee Buckler has held various key positions such as President & CEO, Director at RepliCel Life Sciences Inc., Principal at Highmont Capital Management, Inc., Partner at Restructur Advisors, Vice President, Business and Corporate Development at RepliCel Life Sciences Inc., among others.

With a wide array of experiences ranging from founding and managing companies to serving in editorial and legal roles, Lee Buckler's expertise spans business development, marketing, communication, and strategic management in the biotech and regenerative medicine sectors.

Highlights

Jul 23 · linkedin

Three people with autoimmune diseases (one patient with immune-mediated necrotizing myopathy (IMNM) and two patients with diffuse cutaneous systemic sclerosis (dcSSc), have responded positively to allogeneic CAR-T therapy, marking a first for the "off-the-shelf" cell therapy tech which is engineered CAR-T cells from donors to target CD19, a protein found on the surface of B cells. They also knocked out human leukocyte antigen in the cells and then amplified the cells negative for CD3, in order to prevent conflicts between donor cells and host cells.

CD19 targeting is an emerging therapy for treating B cell malignancies, but it hasn’t successfully been used to treat B cells that have gone rogue, as is the case in autoimmune diseases.

The study, conducted in China and published in Cell on July 15, is the first sign of the potential of allogeneic CAR-T therapies in treating autoimmune diseases

Lee Buckler
Add to my network